Non alcoholic fatty liver disease, insulin resistance, dyslipidemia and atherogenic ratios in epileptic children and adolescents on long term antiepileptic drug therapy.
This study explores the occurrence of Non-alcoholic Fatty Liver Disease (NAFLD), Insulin Resistance (IR), dyslipidemia and atherogenic ratios in epileptic children and adolescents receiving Valproic Acid (VPA), Carbamazepine (CBZ) or both (combination therapy) compared to healthy controls. Abdominal Computerized Tomography (CT), measurements of serum fasting insulin, glucose, serum lipids and liver enzymes were performed in VPA (n = 14), CBZ (n = 14) or both (n = 10) treated non-diabetic non-obese epileptic patients compared to healthy controls (n = 10). Abdominal CT demonstrated characteristics of fatty liver disease in 42.8% of VPA, in 21.4% of CBZ, in 60% of combination therapy treated patients and none of the healthy controls. All of them were overweight and 53.3% had IR. In conclusion VPA therapy was associated with increased risk of IR and NAFLD, while CBZ therapy was associated with dyslipidemia and combination therapy was associated with all these risks.